Iovance Biotherapeutics
Iovance Biotherapeutics, Inc., a pioneering leader in the field of cell therapy, is headquartered in the United States, with significant operations across various regions. Founded in 2011, the company has made remarkable strides in developing innovative treatments for cancer, particularly through its unique tumour-infiltrating lymphocyte (TIL) therapy. This groundbreaking approach harnesses the body’s immune system to target and destroy cancer cells, setting Iovance apart in the biopharmaceutical industry. With a strong focus on advancing personalised cancer therapies, Iovance has achieved notable milestones, including successful clinical trials and collaborations that enhance its market position. The company’s flagship product, Lifileucel, exemplifies its commitment to transforming cancer treatment, offering hope to patients with advanced melanoma and other solid tumours. As Iovance continues to expand its influence, it remains dedicated to improving patient outcomes through innovative therapeutic solutions.
DitchCarbon Score
How does Iovance Biotherapeutics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Education Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Iovance Biotherapeutics's score of 20 is lower than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Iovance Biotherapeutics's reported carbon emissions
Iovance Biotherapeutics, headquartered in the US, currently does not have publicly available data on its carbon emissions, as no specific emissions figures have been reported. Additionally, there are no documented reduction targets or climate pledges outlined by the company. This lack of information suggests that Iovance may still be in the early stages of formalising its climate commitments or reporting its environmental impact. As the biotherapeutics industry increasingly prioritises sustainability, it will be essential for Iovance to establish clear emissions reduction goals and strategies to align with industry standards and expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Iovance Biotherapeutics is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
